𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Parkinson’s disease and mitochondrial complex I: a perspective on the Ndi1 therapy

✍ Scribed by Mathieu Marella; Byoung Boo Seo; Takao Yagi; Akemi Matsuno-Yagi

Publisher
Springer US
Year
2009
Tongue
English
Weight
178 KB
Volume
41
Category
Article
ISSN
0145-479X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of a promoter polymorphism on
The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease
✍ Terrie Rife; Bareza Rasoul; Nicholas Pullen; David Mitchell; Kristen Grathwol; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

## Abstract Transcriptional changes of the enzyme nitric oxide synthase I (NOS1) are believed to play a role in the development of many diseases. The gene for NOS1 has 12 alternative first exons (1A–1L). The 1F exon is one of the most highly utilized first exons in the brain and has a polymorphism

The effect of cueing therapy on single a
The effect of cueing therapy on single and dual-task gait in a drug naïve population of people with Parkinson's disease in northern Tanzania
✍ Lynn Rochester; Danny Rafferty; Catherine Dotchin; Oliva Msuya; Victor Minde; R. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

The incidence of Parkinson's disease (PD) in sub-Saharan Africa (SSA) is greater than thought however, is largely undiagnosed and untreated. This study aimed to evaluate a nonpharmacological approach using cueing therapy to improve gait in drug-naïve PD and the feasibility of delivering rehabilitati

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

West A, Periquet M, Lincoln S, L�cking C
West A, Periquet M, Lincoln S, L�cking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Deleuze J-F, Maraganore D, Levey A, Wood N, D?rr A, Hardy J, Brice A, Farrer M, the French Parkinson's Disease Genetics Study Group, the European Consortium on Genetic Susceptibility on Parkinson's Disease. 2002. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet (Neuropsychiatr Genet) 114:584-591
📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 23 KB